Literature DB >> 18794122

Regulation of apoptosis and caspase-8 expression in neuroblastoma cells by isoforms of the IG20 gene.

Liang Cheng Li1, Jian Rong Sheng, Nirupama Mulherkar, Bellur S Prabhakar, Matthew N Meriggioli.   

Abstract

The IG20 gene undergoes alternative splicing resulting in the differential expression of six putative splice variants. Four of these (IG20pa, MADD, IG20-SV2, and DENN-SV) are expressed in virtually all human tissues. However, investigations examining alternative splicing of the IG20 gene to date have been largely limited to nonneural malignant and nonmalignant cells. In this study, we investigated the expression of alternative splice isoforms of the IG20 gene in human neuroblastoma cells. We found that six IG20 splice variants (IG20-SVs) were expressed in two human neuroblastoma cell lines (SK-N-SH and SH-SY5Y), highlighted by the expression of two unique splice isoforms (i.e., KIAA0358 and IG20-SV4). Similarly, we found enriched expression of these two IG20-SVs in human neural tissues derived from cerebral cortex, hippocampus, and, to a lesser extent, spinal cord. Using gain-of-function studies and siRNA technology, we determined that these "neural-enriched isoforms" exerted significant and contrasting effects on vulnerability to apoptosis in neuroblastoma cells. Specifically, expression of KIAA0358 exerted a potent antiapoptotic effect in both the SK-N-SH and SH-SY5Y neuroblastoma cell lines, whereas expression of IG20-SV4 had proapoptotic effects directly related to the activation of caspase-8 in these cells, which have minimal or absent constitutive caspase-8 expression. These data indicate that the pattern of expression of these neural-enriched IG20-SVs regulates the expression and activation of caspase-8 in certain neuroblastoma cells, and that manipulation of IG20-SV expression pattern may represent a potent therapeutic strategy in the therapy of neuroblastoma and perhaps other cancers.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18794122      PMCID: PMC2760438          DOI: 10.1158/0008-5472.CAN-07-6311

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  35 in total

1.  Potentiation of neuroblastoma metastasis by loss of caspase-8.

Authors:  Dwayne G Stupack; Tal Teitz; Matthew D Potter; David Mikolon; Peter J Houghton; Vincent J Kidd; Jill M Lahti; David A Cheresh
Journal:  Nature       Date:  2006-01-05       Impact factor: 49.962

Review 2.  Alternative splicing: new insights from global analyses.

Authors:  Benjamin J Blencowe
Journal:  Cell       Date:  2006-07-14       Impact factor: 41.582

3.  Purification and properties of Rab3 GEP (DENN/MADD).

Authors:  Toshiaki Sakisaka; Yoshimi Takai
Journal:  Methods Enzymol       Date:  2005       Impact factor: 1.600

Review 4.  Splicing regulation in neurologic disease.

Authors:  Donny D Licatalosi; Robert B Darnell
Journal:  Neuron       Date:  2006-10-05       Impact factor: 17.173

5.  Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN.

Authors:  T Teitz; T Wei; M B Valentine; E F Vanin; J Grenet; V A Valentine; F G Behm; A T Look; J M Lahti; V J Kidd
Journal:  Nat Med       Date:  2000-05       Impact factor: 53.440

6.  A splicing variant of a death domain protein that is regulated by a mitogen-activated kinase is a substrate for c-Jun N-terminal kinase in the human central nervous system.

Authors:  Y Zhang; L Zhou; C A Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-03       Impact factor: 11.205

Review 7.  Genome-wide screening for gene function using RNAi in mammalian cells.

Authors:  Lara M Cullen; Greg M Arndt
Journal:  Immunol Cell Biol       Date:  2005-06       Impact factor: 5.126

8.  MADD, a novel death domain protein that interacts with the type 1 tumor necrosis factor receptor and activates mitogen-activated protein kinase.

Authors:  A R Schievella; J H Chen; J R Graham; L L Lin
Journal:  J Biol Chem       Date:  1997-05-02       Impact factor: 5.157

9.  The human DENN gene: genomic organization, alternative splicing, and localization to chromosome 11p11.21-p11.22.

Authors:  V T Chow; K M Lim; D Lim
Journal:  Genome       Date:  1998-08       Impact factor: 2.166

10.  Role of IG20 splice variants in TRAIL resistance.

Authors:  Bellur S Prabhakar; Nirupama Mulherkar; Kanteti V Prasad
Journal:  Clin Cancer Res       Date:  2008-01-15       Impact factor: 12.531

View more
  14 in total

Review 1.  DENN domain proteins: regulators of Rab GTPases.

Authors:  Andrea L Marat; Hatem Dokainish; Peter S McPherson
Journal:  J Biol Chem       Date:  2011-02-17       Impact factor: 5.157

Review 2.  Alternative splicing as a biomarker and potential target for drug discovery.

Authors:  Kai-qin Le; Bellur S Prabhakar; Wan-jin Hong; Liang-cheng Li
Journal:  Acta Pharmacol Sin       Date:  2015-06-15       Impact factor: 6.150

3.  Akt-phosphorylated mitogen-activated kinase-activating death domain protein (MADD) inhibits TRAIL-induced apoptosis by blocking Fas-associated death domain (FADD) association with death receptor 4.

Authors:  Peifeng Li; Shankar Jayarama; Lakshmy Ganesh; David Mordi; Ryan Carr; Prasad Kanteti; Nissim Hay; Bellur S Prabhakar
Journal:  J Biol Chem       Date:  2010-05-18       Impact factor: 5.157

4.  Down-modulation of expression, or dephosphorylation, of IG20/MADD in tumor necrosis factor-related apoptosis-inducing ligand-resistant thyroid cancer cells makes them susceptible to treatment with this ligand.

Authors:  Liang-Cheng Li; Shankara Jayarama; Tania Pilli; Lixia Qian; Furio Pacini; Bellur S Prabhakar
Journal:  Thyroid       Date:  2013-01       Impact factor: 6.568

5.  Knockdown of MADD and c-FLIP overcomes resistance to TRAIL-induced apoptosis in ovarian cancer cells.

Authors:  Liang-Cheng Li; Shankar Jayaram; Lakshmy Ganesh; Lixia Qian; Jacob Rotmensch; Ajay V Maker; Bellur S Prabhakar
Journal:  Am J Obstet Gynecol       Date:  2011-05-27       Impact factor: 8.661

6.  MADD, a splice variant of IG20, is indispensable for MAPK activation and protection against apoptosis upon tumor necrosis factor-alpha treatment.

Authors:  Bapi Raju V V S N Kurada; Liang Cheng Li; Nirupama Mulherkar; Mahesh Subramanian; Kanteti V Prasad; Bellur S Prabhakar
Journal:  J Biol Chem       Date:  2009-03-16       Impact factor: 5.157

7.  Biallelic MADD variants cause a phenotypic spectrum ranging from developmental delay to a multisystem disorder.

Authors:  Pauline E Schneeberger; Fanny Kortüm; Georg Christoph Korenke; Malik Alawi; René Santer; Mathias Woidy; Daniela Buhas; Stephanie Fox; Jane Juusola; Majid Alfadhel; Bryn D Webb; Emanuele G Coci; Rami Abou Jamra; Manuela Siekmeyer; Saskia Biskup; Corina Heller; Esther M Maier; Poupak Javaher-Haghighi; Maria F Bedeschi; Paola F Ajmone; Maria Iascone; Hilde Peeters; Katleen Ballon; Jaak Jaeken; Aroa Rodríguez Alonso; María Palomares-Bralo; Fernando Santos-Simarro; Marije E C Meuwissen; Diane Beysen; R Frank Kooy; Henry Houlden; David Murphy; Mohammad Doosti; Ehsan G Karimiani; Majid Mojarrad; Reza Maroofian; Lenka Noskova; Stanislav Kmoch; Tomas Honzik; Heidi Cope; Amarilis Sanchez-Valle; Bruce D Gelb; Ingo Kurth; Maja Hempel; Kerstin Kutsche
Journal:  Brain       Date:  2020-08-01       Impact factor: 13.501

8.  MADD is a downstream target of PTEN in triggering apoptosis.

Authors:  Shankar Jayarama; Liang-Cheng Li; Lakshmy Ganesh; David Mardi; Prasad Kanteti; Nissim Hay; Peifeng Li; Bellur S Prabhakar
Journal:  J Cell Biochem       Date:  2014-02       Impact factor: 4.429

9.  Knockdown of IG20 gene expression renders thyroid cancer cells susceptible to apoptosis.

Authors:  Mahesh Subramanian; Tania Pilli; Palash Bhattacharya; Furio Pacini; Yuri E Nikiforov; Prasad V Kanteti; Bellur S Prabhakar
Journal:  J Clin Endocrinol Metab       Date:  2009-02-03       Impact factor: 5.958

10.  Genome-wide analysis of alternative splicing in medulloblastoma identifies splicing patterns characteristic of normal cerebellar development.

Authors:  Francesca Menghi; Thomas S Jacques; Martino Barenco; Ed C Schwalbe; Steven C Clifford; Mike Hubank; Jonathan Ham
Journal:  Cancer Res       Date:  2011-01-19       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.